General contact

Head Office
Novartis International AG
CH-4002 Basel

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

Targeted Research

Targeted Research accelerates development and improves results

At Novartis Oncology, research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and knowledge of disease pathways. Our targeted research strategy leverages biomarkers and targeted drug development focused on individual patients.

Our approach speeds the availability of targeted treatments through:

  • Enhanced screening and identification of promising compounds and combinations.
  • Better patient selection and response prediction biomarkers to increase likelihood of success.
  • Delivery of targeted treatments with companion diagnostics to optimize patient outcomes.
Targeted Research

Thanks to this approach, the Novartis Oncology Pipeline is one of the strongest and most productive pipelines in the industry.

"Together, we discover innovative medicines that transform the way people live with cancer and targeted diseases".